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Abstract
Whole genome sequencing is increasingly used to study phenotypic variation among infectious pathogens and to
evaluate their relative transmissibility, virulence, and immunogenicity. To date, relatively little has been published on
how and how many pathogen strains should be selected for studies associating phenotype and genotype. There
are specific challenges when identifying genetic associations in bacteria which often comprise highly structured
populations. Here we consider general methodological questions related to sampling and analysis focusing on
clonal to moderately recombining pathogens. We propose that a matched sampling scheme constitutes an
efficient study design, and provide a power calculator based on phylogenetic convergence. We demonstrate this
approach by applying it to genomic datasets for two microbial pathogens: Mycobacterium tuberculosis and
Campylobacter species.
Background
In infectious disease, host and pathogen factors interact to
result in the observed severity of illness. Genetic changes
within pathogen populations can result in a spectrum of
virulence, drug resistance, transmission rates, and im-
munogenicity - all highly relevant phenotypes in the study
of infectious disease. Host variables that affect susceptibil-
ity to infection, such as age, immunodeficiency, and nutri-
tional status are more easily measured and have been
studied for some time, whereas the study of pathogen spe-
cific determinants of disease risk is more recent. One of
the first to use the term molecular epidemiology and apply
it to infectious disease agents was E. Kilbourne. In his
1973 paper ‘Molecular epidemiology of influenza’,h ed i s -
cussed antigenic variation as a cause of the influenza pan-
demics of the 20th century [1]. The ability to type molecular
traits of pathogens, such as surface proteins or highly
variable DNA segments, allowed the characterization of suf-
ficient strain-to-strain variation to determine when trans-
mission of disease occurred [2] as well as surveillance of the
frequencies of different strain types over time [3]. As se-
quencing became sufficiently high throughput to allow for
whole genome analysis, the typing resolution immediately
reached the limit for heritable strain differences and has ac-
cordingly gained momentum in the study of infectious dis-
ease [4-7].
Molecular epidemiologic tools have not only enabled
disease surveillance and the study of transmission chains,
but also have facilitated the study of pathogen biology, by
allowing researchers to compare the transmissibility, im-
munogenicity, or other phenotypes that vary among strain
types or lineages and correlate these differences with spe-
cific changes in the genome [8,9]. Large numbers of
pathogen samples are often gathered for clinical diagnostic
purposes. For pathogens of high outbreak potential, sam-
ples may be collected for surveillance purposes. The short
evolutionary times corresponding to outbreaks often mean
that samples of transmitted pathogens are clonal. The
availability of samples from diagnostic and outbreak set-
ting, and the DNA sequences generated from them,
means that investigators are faced with questions about
which and how many pathogen isolates to sequence and
which analytical techniques to use to maximize efficiency
and power. These questions are especially relevant for
studies of whole-genome sequences (WGS) that will
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great majority of which will be noise, that is, neutral muta-
tions not related to the phenotype of interest.
The methods underlying human genome-wide associ-
ation studies (GWAS) and whole exome sequencing have
advanced significantly in the past 10 years, and are now
more rigorous and standardized across studies of different
human traits and diseases [10,11]. These advancements
have included recommendations on study design includ-
ing subject selection strategies and sample size to uncover
elements of varying frequency and effect sizes. These
methods are most well developed for single nucleotide
polymorphism (SNP) changes in typing data (as opposed
to whole genome sequences) and make implicit assump-
tions about the human genomic structure, diploidy, and
recombination rates [12-14]. The situation is different in
bacteria where recombination and genetic mutation rates
vary among species, from highly clonal organisms like
Mycobacterium tuberculosis (MTB), to the rapidly recom-
bining/sexual Streptococcus pneumoniae. In contrast to
disease states in humans, pathogen phenotypes of interest
are often those that provide a selective advantage for the
organism. Several different methods are in current use for
the study of genome wide variation of pathogens that, in
contrast to human genetic association studies, can fre-
quently leverage information about positive selection.
Despite this, the field has not yet defined accepted meth-
odologies and standards for statistical testing of variants
on a whole genome scale. In this paper we review the lit-
erature on genotype-phenotype studies and analytical
techniques focusing on MTB as an example. We propose
a matched genome sampling and analysis strategy to
optimize power for pathogens that are clonal to moder-
ately sexual. We provide an associated power and sample
size calculator and demonstrate and validate the method
using two genomic datasets: one from MTB and one from
Campylobacter species.
Methods
The methods outlined below were used for the applica-
tion of the sampling strategy.
Strain isolation, culture, sequencing, and variant call-
ing are detailed in the original publications [15,16].
Phylogeny construction
MTB: The phylogeny was constructed based on the whole
genome multiple alignment. As MTB populations are con-
sidered to be predominantly clonal, most of the genome is
thought to support a single consensus phylogeny that is not
impacted significantly by recombination [17]. A superset of
SNPs relative to reference strain H37Rv [18] was created
across the clinical isolates from the variant caller SNP re-
ports. SNPs occurring in repetitive elements including
transposases, PE/PPE/PGRS genes, and phiRV1 members
(273 genes, 10% of genome) (genes listed in reference [19])
were excluded to avoid any concern about inaccuracies in
the read alignment in those portions of the genome. Fur-
thermore, SNPs in an additional 39 genes previously associ-
ated with drug resistance [20] were also removed to
exclude the possibility that homoplasy of drug resistance
mutations would significantly alter the phylogeny. After ap-
plying these filters the remaining SNPs were concatenated
and used to construct a parsimony phylogenetic tree using
PHYLIP dnapars algorithm v3.68 [21] with KZN-DS [22]
strain as an outgroup root. We constructed a phylogeny by
two methods. First, using Bayesian Markov chain Monte
Carlo (MCMC) methods as implemented in the package
MrBayes v3.2 [23] using the GTR model and a maximum
likelihood tree using PhyML v3.0 [24]. Second, using the
GTR model with eight categories for the gamma model and
the results were consistent with the PHYLIP Phylogeny.
Campylobacter
Using multi-local sequence typing data, a phylogeny was es-
timated using ClonalFrame [25], a model-based approach
to determining microevolution in bacteria. This program
differentiates mutation and recombination event on each
branch of the tree based on the density of polymorphisms.
ClonalFrame was run with 50,000 burn in iterations and
50,000 sampling iterations. The consensus tree represents
combined data from three independent runs with 75% con-
sensus required for inference of relatedness. Recombination
events were defined as sequences with a length of >50 bp
with a probability of recombination >=75% over the length,
reaching 95% in at least one site.
Analysis
The number of mutations, insertions, or deletions (of
any size) differing between each strain pair was summed
across each locus for the eight strain pairs for each of
the two datasets belonging to MTB or Campylobacter.
The upper 95% confidence interval for the average num-
ber of mutations/locus across the eight pairs was used as
a mean of the null Poisson distribution. All genes with
larger counts than expected under this null distribution
were considered to be significantly association with the
resistance phenotype.
Results and Discussion
Literature search
We first defined five cornerstones of a systematically de-
signed microbial genotype-phenotype association study:
(1) a well-defined phenotype of interest, that can be mea-
sured/classified with negligible error; (2) some under-
standing of the effect size for that phenotype, for example
is it influenced by many genetic variants each with small
or incremental effect, or are there fewer variants with a
large effect?; (3) estimates of the number of whole
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strategy that may include the sequencing of pathogens seri-
ally sampled over time from the same patient, the study of
strains matched by some predefined characteristic, a ‘ran-
dom’ subsample, or an ‘exhaustive’ complete sample; and
(5) a defined statistical analysis strategy that maximizes
power and minimizes the rate of false positives.
We performed a systematic search of the literature to de-
termine which sampling and analytical strategies (the five
components above) have been applied to the study of MTB
biology using whole genome sequences. We sought articles
studying one of the following aspects of MTB biology:
immunogenicity, pathogenicity, virulence, transmissibility,
drug resistance, or fitness using whole genome sequences.
Search terms, inclusion and exclusion criteria are detailed
in Table 1. We searched PubMed on 1 September 2013 and
identified 216 abstracts, and included 16 studies (Figure 1,
Table 2).
Phenotype
Most of the studies (13/16) focused on the MTB resist-
ance phenotype to a wide range of drugs. Three other
studies examined other strains including: (1) strains
causing extrapulmonary tuberculosis; (2) strains with a
smooth phenotype; and (3) strains typed as Beijing using
spoligotyping.
Effect sizes and a priori power calculations were not
explicitly discussed in any of these studies.
Sampling
Half of the 16 studies sampled strains in time-course, ei-
ther in laboratory-evolved strains (five studies), or in
serial samples from the same patient (three studies). In
all cases, strains were initially drug sensitive but later
acquired a drug resistance phenotype. In the other eight
studies, clinical MTB samples were obtained from dif-
ferent TB patients, and generally involved the study of
more distantly-related strains than in the time-course
studies. In general strains were sampled more or less
randomly to include strains with and without the
phenotype. Seven of the non-time-course studies were
published within the last year.
Analysis
In the time-course studies, few mutations occurred and
it was generally tractable to identify all novel mutations
and infer their role in resistance. In the other studies,
only two of eight were able to make specific genomic
Table 1 PubMed Search terms and inclusion and exclusion criteria
Search purpose Search terms Inclusion criteria Exclusion criteria
Identify studies of Pathogen
Biology using whole
genome sequencing and
analysis
‘genome sequencing’ AND ‘tuberculosis’
AND (‘drug resistance’ OR ‘virulence’ OR
‘immunogenicity’ OR ‘transmissibility’ OR
‘fitness’)
All abstracts describing the use of WGS data to
identify genes related to pathogen
immunogenicity, virulence, transmissibility, drug
resistance, or fitness
(1) Review articles
(2) Studies that
published new
sequence data only
(3) Studies that did
not study MTB
bacteria and its
biology
In all PubMed fields
(4) Studies that only
assess mutation rates
in non-clinical
settings
216 abstracts retrieved 
Bio Search Terms in 
Pubmed on 9-2013
14 abstract included 
202 excluded: 
￿ 27 review 
￿ 2 published new 
sequence only 
￿ 165 did not study 
MTB (27), or WGS 
(138). 
￿ 3 studied bacterial 
mutation rates in 
nonclinical settings 
￿ 3 studied MTB 
epidemiology and not 
biology 
Data extracted: 
1.  Year published 
2.  # strains sequenced 
3.  The 5 components of a 
genotype-phenotype 
association study 
3.1. Phenotype of 
interest 
3.2. Notions of 
heritability 
3.3. Sampling 
strategy/Power 
calculation 
3.4. Analysis strategy 
4. Any gene-phenotype 
associations that were 
made
2 abstracts added from 
related citations section:  
16 abstracts 
+ 2 
Figure 1 Flow chart detailing literature search.
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Author Reference Year Strains
sequenced (n)
Stated study purpose
a Clinical
strains?
Time series? Method Report specific
genotypic association?
Zhang et al. [26] 2013 161 Identify drug resistance
genes
Yes No Phylogenetics and comparison of rates
with poisson distribution
Yes; list of genes provided
Farhat et al. [15] 2013 124 Identify drug resistance
genes
Yes No Phylogenetics and convergence
analysis
Yes; list of genes provided
Lin et al. [27] 2013 2 Identify drug resistance
genes
Yes No Comparison with reference
mycobacterial strains
No
Wu et al.[ 28] 2013 4 Identify Beijing associated
pathways
Yes No COG enrichment of genes with snps General pathways rather than
individual genes
Das et al. [29] 2013 5 Identify genes related to
extrapulmonary TB
Yes No COG enrichment of genes with snps General pathways rather than
individual genes
Ilina et al. [30] 2013 4 Identify drug resistance
genes
Yes No Comparison with reference
mycobacterial strains
No
Abrahams et al. [31] 2013 - Identify resistance targets(s)
for novel imidazole
No Yes: spontaneous mutants
resistant to drug and their
sensitive ancestor
Identification of all mutations Yes qcrb
Supply et al. [32] 2013 5 Identify genes associated
with smooth TB phenotype
Yes No Comparison with reference
mycobacterial strains
General pathways rather than
individual genes
Hartkoorn et al. [33] 2012 - Identify resistance targets(s)
for pyridomycin
No Yes: spontaneous mutants
resistant to drug and their
sensitive ancestor
Identification of all mutations Yes acyl-carrier-protein inha
G. Sun et al. [34] 2012 7 Identify drug resistance
genes
Yes Yes: serial samples from same
patient
Identification of all mutations No; but list of potential
candidates with new fixed
mutations provided
Grzegorzewicz et al. [35] 2012 - Identify resistance targets(s)
for novel compound
Adamantyl Urea
Yes Yes: serial samples from the
same patient
Identification of all mutations Yes mmpl3
Casali et al. [36] 2012 59 Identify drug resistance
genes
Yes No Phylogenetic tree and parallel
evolution and convergence
Yes rpoc
Tahlan et al. [37] 2012 - Identify resistance targets(s)
for novel compound
SQ109
No Yes: spontaneous mutants
resistant to drug and their
sensitive ancestor
Identification of all mutations Yes mmpl3
La Rosa et al. [38] 2012 - Identify resistance target(s)
for 1,5-diarylpyrrole
derivative BM212
No Yes: spontaneous mutants
resistant to drug and their
sensitive ancestor
Identification of all mutations Yes mmpl3
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1Table 2 Literature search results (Continued)
Comas et al. [39] 2011 10 Identify drug resistance
genes
Yes Yes: serial samples from the
same patient
Identification of all mutations in rpoc.
Assessment of convergence across
different strain pairs
Yes confirmed rpoc
Manjunatha et al. [40] 2006 - Identify resistance targets(s)
for PA-824
No Yes: spontaneous mutants
resistant to drug and their
sensitive ancestor
Identification of all mutations Yes Rv3547
aThe term ‘phenotype related genes’ is used loosely here to describe genes that are associated with but not necessarily causative of the phenotype.
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1associations supported by formal assessments of statistical
significance; both these studies sequenced a relatively large
number of genomes (>100), and used phylogenetic ances-
tral reconstruction in their analysis of mutations relevant
to the phenotype [15,26]. Two studies [15,36] used phylo-
genetic convergence (described below) to select candidates
for association with the drug resistance phenotype. In the
other six studies, the phenotype-genotype associations
were of a more descriptive, less formal nature.
Across all studies, a common theme was the use of tests
for positive selection and phylogenetics to differentiate be-
tween genetic variation related to strain ancestry and those
relevant to the phenotype [15,36]. There are also examples
from non-TB pathogens [16,41]. In the phylogenetic con-
vergence test mentioned above, a relatedness tree, con-
structed using the whole genome data is used to identify
genes that accumulate frequent mutations synchronous
with the acquisition of the phenotype of interest. Phylogen-
etic convergence has several advantages well-suited to the
study of microorganisms. Most notably, by focusing only
on the genetic changes that coincide with the independent
appearances of the phenotype, it ignores false-positive asso-
ciations due to clonal population structure, namely the gen-
etic relatedness of the strains [15,16,36,41,42]. It can
therefore be applied to both clonal and sexual/recombining
pathogens as long as recombination is taken into account
in the phylogenetic tree construction [43]. For highly re-
combining pathogens, the tools of human GWAS might be
appropriate, with some modifications [44,45].
Sampling and analysis strategy
The literature review highlights the success of time-course
WGS, either within patients or in vitro, to identify the gen-
etic bases of clinically-important phenotypes. However
time-course samples are often difficult to obtain, particularly
in clinical settings, and may not always be generalizable to
the larger population of pathogens [46]. In contrast to time-
courses, ‘cross-sectional’ samples of strains routinely col-
lected for patient diagnosis or public health surveillance are
both easier to obtain and may provide a more comprehen-
sive, global picture of a pathogen’s adaptive landscape.
A major challenge posed by studying diverse clinical
s t r a i n si st h a tt h es a m p l e dp o p u l a t i o no fp a t h o g e n sm a y
contain population structure related to the shared ancestry
of the strains. Populations are considered structured when
they include subpopulations among which the frequency of
genotypes differs systematically. Population structure, a form
of non-independence of observations, can be seen when
pathogen strains are isolated from disease outbreaks or dir-
ect transmission chains, or clusters, and compared with
non-clustered strains; The study of pathogen subpopulations
when they also preferentially share the phenotype of interest,
can lead investigators to wrongly associate the subpopula-
tion genotype, shared by virtue of ancestry alone, with the
phenotype of interest. This type of confounding bias is a
well-recognized problem in human GWAS [11,47-49].
Whereas different methods such as Principle Compo-
nents analysis, mixed effects models and phylogenetic
convergence can be used to correct for population struc-
ture [11,47-51], adopting a careful sampling strategy can
minimize the impact of - or even capitalize on - population
structure. Drawing parallels from case-control study design
in epidemiology and human GWAS [47] we propose that
sampling ‘matched’ pairs of closely-related strains with dif-
ferent phenotypes can not only control for population
structure but can also deliver higher power relative to
sampling randomly from strain collections. The matching
procedure we propose addresses population structure and
improves power by ignoring the shared variants within a
subpopulation and focusing only on the recently evolved
differences, thus reducing the number of variables tested
and improving power. The sequence data generated using
matched sampling can be analyzed using a simplified form
of phylogenetic convergence by: (1) identifying the recently
evolved mutations by pairwise alignment of a sequence
from a strain with the phenotype of interest with a closely-
related strain lacking the phenotype; (2) counting the num-
ber of mutations across several such pairs; and (3) compar-
ing these counts either to a null distribution generated
using a non-parametric permutation test [15], or simply to
a Poisson or Binomial distribution, as we will discuss and
demonstrate in the next sections.
Assuming a binary phenotype of interest that has been
clearly defined, we propose to match strains using data
from traditional strain typing such as pulsed-field gel
electrophoresis and multi-locus sequence typing that is
often already available for the banked strains, especially
under surveillance for public health purposes. Using this
lower resolution typing data, a phylogenetic tree can be
constructed, accounting for recombination as needed
using methods such as ClonalFrame [16,25]. Figure 2A
displays a hypothetical tree topology obtained for a sam-
ple of 16 MTB clinical strains constructed using their
MIRU-VNTR pattern [52]. Figure 2B demonstrates the
matched sampling strategy. For each phenotype positive
(ph+) strain, a neighboring phenotype negative (ph-)
strain is selected such that the phylogenetic distance be-
tween the pair of strains is minimized. Only one ph- and
one ph+ strain is sampled per clade. If more than one
strain is equidistant, then one is selected at random. The
larger phylogenetic tree is thus reduced to a set of
matched ph+ and ph- pairs.
Power calculations to optimize genotype-phenotype
association studies
To design a genotype-phenotype association study, know-
ledge about the optimal number of pathogen genomes to
sample is necessary. Here we define the sample size n as
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a nominal power of >80% for detecting a true association,
accepting a false positive association rate of no higher than
0.05. Our goal is to identify genomic variants, for example
mutations or recombination events that confer a fitness
advantage when the phenotype of interest such as anti-
biotic resistance, virulence, evolves under selective pres-
sure. These positively selected variants are expected to be
more prevalent in strains with the phenotype of interest
(ph+). Below, we will describe two methods to identify
genomic variants associated with this phenotype of inter-
est. The first,‘site-level’ method, uses individual nucleotide
sites as the basic level of genetic variation. However, this
method can also be applied to other levels of variation, in-
cluding the presence of absence of genes, or clusters of
mutations that are transferred together by recombination
and can thus be considered as a unit. This method is
therefore applicable to clonal pathogens that evolve al-
most entirely by point mutation, as well as to moderately
recombining pathogens, in which recombinant parts of
the genome can be identified computationally [53-55] and
considered as a single ‘site’. In the second, ‘locus-level’
method, we model a scenario in which different mutations
within the same gene or locus can have a similar pheno-
typic effect, for example the loss of function by introdu-
cing stop codons at different points in the gene, providing
additional evidence for the importance of that gene for a
particular phenotype.
In the site-level method, for an organism with genome
of length k and an average distance (or number of vari-
ants) s between each pair of strains, we can define a null
hypothesis for the distribution of the number of variants lj
at a particular neutral site (j) in the genome (in the ph+
relative to the ph- strains) across the n pairs. In particular,
if the site j is not under selection, then s/k should be a rea-
sonable estimate of the rate of neutral variation, and under
the null hypothesis, lj is a Binomial random variable corre-
sponding to n trials with a success probability pNull=s/ k.
Under the alternative hypothesis that site j is under posi-
tive selection, lj is a binomial random variable with n trials
and success probability fsite which is greater than s/k. fsite is
related to the phenotypic effect size of the variant, as a
higher frequency of a variant will result from stronger
positive selection, that is, higher fitness of the variant in
A
B
L1 L2 L3 L4 L5
24421
24421
24422
13423
33423
33423
32321
32321
42324
42324
42323
51131
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51221
5122
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1
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4
Figure 2 Demonstration of the selection strategy. (A) Example initial MIRU-VNTR phylogeny constructed for selection of strains for sequencing and
analysis. Grey circles represent strains with the phenotype of interest (ph+strains), the white circles represent strains without the phenotype of interest
(ph- strains). The Table with columns L1-5 represent the variable number of tandem repeat at each locus L. (B) Example of selection methodology: For
each ph+strain (grey circle) a neighboring ph- strain is selected such that the distance between the two strains in the phylogeny is minimized. Each
control or study strain is only sampled once. The resultant tree of selected strains will consist of matched study and control strains.
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would be a selective sweep that results in all members of
the ph+population carrying the same variant in which
case fsite would be 1. In a previous genotype-phenotype as-
sociation study of drug resistance in MTB [15], the lowest
frequency of a single nucleotide (‘site level’) variant with a
known fitness advantage was estimated at 4% (f=0. 04 )
(rpoB codon 455 in rifampicin (RIF) resistant strains),
whereas the highest was estimated at 52% (f=0.52 )(rpoB
codon 450).
As observed for rpoB, more than one nucleotide site
in a locus can carry a fitness conferring variant; we can
thus formulate a locus-level test by defining a null distri-
bution for the sum of the variant counts in a locus,
li_locus. If locus i of length gi is not under selection, with
the same parameters s and k defined above, then the dis-
tribution of li_locus can be approximated by a Poisson dis-
tribution with a rate =nsg i /k. Under the alternative
hypothesis, this locus is under selection and the ex-
pected number of mutations is nf locus, which is larger
than nsg i /k. Similar to fsite, flocus is related to the col-
lective fitness advantage conferred by its variants. For
example, in the study cited above, flocus was estimated to
be 0.30 to 1.5/locus/ph+ strain for the thyA locus for
MTB p-aminosalicylic resistance, and rpoB locus for RIF
resistance, respectively [15]. The test will have a different
power for different values of fsite/locus. Because this ana-
lysis involves testing all the sites and loci with observed
variation, a correction for multiple testing is needed. We
use the Bonferroni correction, assuming that the upper
limit for the number of variable sites across the sample
is ns , and the number of variable loci to be 1- e
-n g
i
s/k
(from the Poisson distribution). In Figures 3, 4, and 5,
we provide power calculation results as a function of n, s
and f using the 4.41 Mbp MTB genome as an example.
Here we calculated the expected power by integrating
across the distribution of locus lengths gi for the MTB
reference genome H37Rv. Based on previous data from
fingerprint-matched MTB, our power calculations ex-
plored a range of between-strain genetic distances (s)
from 50 to 300 mutations [4].
In the case of MTB, we found that high power (>80%)
could be achieved by sequencing 50 to 100 strain pairs
(matched at a distance of s= 100 variants) to detect a
‘rare’ drug resistance variant in >5% of the ph+ strains
(fsite >0.05; Figure 3) or a locus with a low mutation rate
of 0.25/locus/ph+ strain (flocus >0.25; Figure 4). The ad-
vantage of performing a locus-level analysis is that we
expect flocus > fsite because flocus is proportional to the
sum of fsite over all sites under selection in the locus.
The number of tests performed in a locus-level analysis
is several orders of magnitude lower than with a site-
level analysis because a bacterial genome contains on
the order of 10
6 sites, but only 10
3 genes (loci). We
performed similar calculations for Campylobacter (k =
1.64 Mbp), assuming a higher matching distance s =300
that is expected for multi-locus sequence typing (MLST)
of this pathogen [16]. With 50 to 100 strain pairs of
Campylobacter the lowest flocus that can be detected with
>80% power is 0.60 (Additional file 1: Figure S1), higher
than for MTB (Figure 4).
We next explored how power depends on the genetic
distance between sampled genomes. Figure 5 demon-
strates that considerable power gains can be achieved by
sampling strain pairs that are close genetic relatives
(low s). This is because, for a given value of fsite or flocus,
raising s decreases the ratio of selected to neutral vari-
ants, thereby decreasing the signal to noise ratio.
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Figure 3 Power of the matched convergence test for identify
nucleotide sites associated with a phenotype of interest. The
average genetic distance between matched strains was set to an
intermediate level of s=100 mutations. Colors represent increasing
values of site effect size fsite.
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Figure 4 Power of the matched convergence test to identify
loci associated with a phenotype of interest. The average
distance between matched strains was set at s=100 mutations.
Colors represent increasing values of locus effect size flocus.
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http://genomemedicine.com/content/6/11/101The power calculator is provided with this manuscript
as an R function (Additional file 2), and allows the user
to tune all the parameters described to provide power
estimates for different effect sizes, different pathogen
genome sizes, and different levels of genetic relatedness.
Application to genomic data from MTB and
Campylobacter species
We applied the sampling strategy described in Figure 2 to a
set of 123 clinically isolated unmatched MTB genomes pre-
viously analyzed using phylogenetic convergence [15]
(Additional files 3 and 4). Repetitive, transposon, and
phage-related regions were removed as putatively recom-
binant or as error-prone regions of the alignment. Of the
123 strains, 47 were resistant to one or more drugs (ph+)
and the rest were sensitive (ph-). As different fingerprinting
methods were used for the different strains in this study
and for demonstration purposes we used the phylogeny
constructed using whole genome single nucleotide poly-
morphisms to match strains. We chose eight pairs of
strains using this selection strategy (Figure 6). We then
counted the recent mutational changes (single nucleotide
polymorphisms; SNPs) between each pair of strains. The
a v e r a g ed i s t a n c e( s) between pairs was 109 SNPs and was
in the range of 12 to 254 SNPs. We calculated the number
of changes per gene across the eight pairs and compared
this number to a Poisson distribution of mutations ran-
domly distributed across branches as the null distribution.
We then identified the tail of the distribution, containing
genes with a high number of changes highly associated with
drug resistance (Figure 7). Overall, 12 genes and non-
coding regions were found to be associated with drug re-
sistance using only 16 out of 123 strains (13%) used in the
original analysis. The analysis identified katG, embB, rpoB
(well known drug resistance determinants) as well as top
new candidates from the previous full analysis of all 123 ge-
nomes: ponA1, ppsA, murD,a n drbsk.T h i ss e l e c t i o ns t r a t -
egy and analysis recovered 67% of the candidates identified
with the full analysis, but used only 13% of the data, dem-
onstrating the superior power of the matched convergence
analysis to the general unmatched test.
Second, we applied the same method to a set of 192
Campylobacter coli and jejuni isolates used by Sheppard
et al. in an association study to identify the factors respon-
sible for adaptation to cattle and chickens [16] (Additional
files 5 and 6). Sheppard et al. associated the presence or
absence of unique 30 bp ‘words’ with the host specificity
phenotype and controlled for population structure by
comparing the real word counts with word counts gener-
ated along the tree through Monte Carlo simulations. We
applied our method to a subset of 29 strains enriched in
the phenotype of host switching that Sheppard et al. had
used in their initial analysis. After correcting for recom-
bination and constructing the phylogeny using Clonal-
Frame, we phylogenetically matched 8 pairs of strains that
had undergone host switching (Figure 8). Five switches
were estimated from cattle to bird or human, and three
were from bird to human hosts. We counted the pairwise
differences across the eight pairs, grouping insertions/de-
letions and mutations by gene and compared the distribu-
tion to the expected Poisson distribution (Figure 9). We
associated two consecutive genes: surE and Cj0294, both
of which were present in cattle-associated strains but ab-
sent in chicken-associated strains. These genes mapped to
a vitamin B5 biosynthesis region, which Sheppard et al.
had previously found to affect Campylobacter growth in
the presence or absence of vitamin B5 [16]. In addition,
our approach associated 105 additional genes (Additional
file 7: Table S1). Thus, using the convergence method and
focusing on genes rather than 30 bp words, we were able
to detect the experimentally-validated vitamin B5 region
of the Campylobacter genome, among other potential
genes involved in host switching that had been observed
by Sheppard et al. using a much smaller dataset.
Our power calculations rely on a well-defined pheno-
type that can be measured without error. The phenotype
is also assumed to be binary, or at least divisible into
two binary states; therefore, the calculations cannot be
easily extended to quantitative traits. Knowledge about
the expected effect size for different phenotypes is also
important for these calculations and prospective study
design. Among the studies reviewed, we found the effect
size to be infrequently reported for MTB. Here we pro-
vide empirical effect sizes estimated from a previous
MTB drug resistance study [15] as a reference point for
future studies.
Our approach also assumes that a certain amount of
previously collected antigen or genotyping data is avail-
able to allow for building a phylogeny and selecting pairs
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Figure 5 Power of the matched convergence test at the locus
level as a function of genetic distance (s) between matched
strains pairs. Smaller s indicates closer genetic relatedness between
strain pairs.
Farhat et al. Genome Medicine 2014, 6:101 Page 9 of 14
http://genomemedicine.com/content/6/11/101of strains to sequence. When sequence data are already
available, this method can still be used to select strains
for paired analysis, providing a simple control for popu-
lation structure and a more simplified analysis strategy.
If no typing data are available, alternatives may still exist
- for example, using epidemiological data that link
strains within a particular outbreak. In each of these sce-
narios, perfect matching to form pairs of monophyletic
strains may not always be possible, but given the rela-
tionship of the matching distance to power demon-
strated above, we argue for matching as many strains as
possible and as closely as possible. The analysis of the
total dataset of all monophyletic and paraphyletic pairs
can be performed via ancestral reconstruction and a
more general phylogenetic convergence method (‘phyC’
[15]) rather than the simplified pairwise analysis de-
scribed here.
Our power calculations, like all models, make neces-
sary simplifications and assumptions. For example, we
assume that neutral variants are distributed randomly
across the whole genome. This may not necessarily be
the case as some pathogen genes may contain mutation
or recombination hot spots. Some adjustment for such a
scenario could be made by using a higher average rate of
variation than the one expected, that is, testing power
under a pairwise distance s
† amplified by a factor m>1
0.03
Figure 6 Phylogeny of MTB strains chosen for genotype-phenotype analysis. Dots indicate the presence of the drug resistant phenotype.
The tree demonstrates the matching of strains with and without the drug resistance phenotype.
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Figure 7 Distribution of SNPs/locus across the eight pairs of
MTB genomes. Observed counts are represented by black bars. The
dashed line represents the upper 95% confidence bounds on a
Poisson distribution with the observed number of mutations.
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Figure 8 Phylogeny of Campylobacter strains. Branches highlighted in green lead up to the strain pairs chosen for genotype-phenotype association.
Colored circles denote host specificity: red=cattle, green=chicken, purple=wild bird/non-host, orange=human.
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Figure 9 Distribution of variants/locus across the eight pairs of Campylobacter genomes. Observed counts are represented by black bars.
The dashed red line represents the upper 95% confidence bounds on a Poisson distribution with the observed number of variants. Variant counts
per locus for surE and Cj0294 are highlighted.
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http://genomemedicine.com/content/6/11/101where s
†=m s expected for a range of m. The framework
and power calculations presented here represent a step
toward more systematic and prospective genotype-
phenotype study design for microbial pathogens, and
can provide the basis for more refined power calcula-
tions (for example, accounting for continuous rather
than binary phenotypes, or for analysis of un-matched
strains).
Conclusions
The improved ability to study the evolution of clinical
strains will be an important advance for the study of patho-
gens as they spread. Thus far, most of our understanding of
infectious disease has focused on the epidemiological study
of host risk factors, or on the in vitro study of the pathogen.
The rich information contained in whole genomes of clin-
ical pathogens - isolated as they adapt to their host and
cause disease - provides a new and complementary per-
spective on pathogen biology. Here we have shown how
clonal to moderately sexual strain collections, originally as-
sembled for epidemiological purposes, using appropriate
sub-sampling schemes, can empower genome-level associ-
ation studies and reveal genotype-phenotype associations,
increasing our understanding of pathogen biology and
adaptation.
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